FDA accepts New Drug Application (NDA) for palovarotene as first potential treatment worldwide for fibrodysplasia ossificans progressiva

NDA for this oral, investigational, selective RARγ agonist for prevention of heterotopic ossification in people with this progressive disabling and ultra-rare genetic disorder is primarily based on data from the ongoing open-label, single-arm MOVE trial.

Source:

Biospace Inc.